Sign inJoin waitlistJoin the waitlist

Holly Edington

Pediatric Hematology-Oncology · Novant Health

Credentials: · · · ·

History

Novant Health
Present

Pediatric Hematology/Oncology
Emory University School of Medicine
2018–2021
Pediatrics
Old Dominion University
2015–2018
Univ of Toledo Coll of Med
2011–2015
University of North Carolina at Chapel Hill (Biology and Spanish

Research

T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome
Blood · 2022 · 34 citations
FcγRIIa ligation induces platelet hypersensitivity to thrombotic stimuli
American Journal Of Pathology · 2013 · 30 citations
T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary…
Journal of Clinical Immunology · 2021 · 21 citations

SC
Shanmuganathan Chandrakasan
4 papers · 3 as a resident
TM
Tamara Miller
3 papers
Andrew Bukowinski
2 papers
CB
Carolyn Bennett
2 papers
Erika Friehling
2 papers
James Ford
2 papers
Jeremy Rubinstein
2 papers
Joanna Robles
2 papers
Julie Rivers
2 papers
Karen Chisholm
2 papers
Lianna Marks
2 papers
MK
Madison Kavanaugh
2 papers · 2 as a resident

Clinical trials

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2022–2030